Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Zhuhai United Laboratories Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Other

Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

Medshine Discovery Inc.

Shandong Danhong Pharmaceutical Co., Ltd.

Zhongshan Ophthalmic Center, Sun Yat-Sen University

Shangdong Danhong Pharmaceutical Co., Ltd.

Zhi Luo

Haiying He

Jian Li

Shuhui Chen

Xiaolin Li

Peng Li

Songliang Wu

Yuan Chen

Zheng Wang

Weidong Li

Yuhe Wang

Dakun Qin

Guoping Hu

Yaxun Yang

Yizhi Liu

Yandong Wang

Lele Yang

Hualing Xiao

Chunyan Du

Liang Shen

Minggao Zeng

Fei Hao

Jianfeng Mou

Chuan Wang

Fengying Guo

Guoqing Li

Lijuan Hou

Xinxin Wen

Chong Su

Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

Compound for use in retinal diseases

A crystal form of a pyridinylphenyl compound and a preparation method therefor. Use of the crystal form in the preparation of a medicament of treating related diseases is also comprised.

Crystal form of pyridinylphenyl compound and preparation method therefor

A composition includes a compound as shown in formula (I). The compound and composition can be used in the preparation of a drug for treating ophthalmic diseases.

Composition of lanosterol prodrug compound, preparation method therefor and use thereof

Disclosed are a process route of a compound of a compound of formula (IV), a crystal form and a preparation method therefor. Also disclosed is an application of the crystal form in preparation of drugs for treating diseases associated with SSAO.

Process route of compound of formula (IV), crystal form and preparation method therefor

A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound

The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases. 

Steroid derivative FXR agonist

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. 

SSAO inhibitor

The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

Crystal form of lanosterol prodrug compound and application thereof

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. 

Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof

Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Crystal form of orexin receptor antagonist compound, and preparation method and application thereof

Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Growing community of inventors

Shanghai, China

Zhi Luo